Land: Storbritannia
Språk: engelsk
Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)
Dipyridamole
Viatris UK Healthcare Ltd
B01AC07
Dipyridamole
100mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02090000; GTIN: 5016695300375
PERSANTIN 100MG TABLETS (dipyridamole) PATIENT INFORMATION LEAFLET READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE * Keep this leaflet. You may need to read it again. * If you have any further questions, ask your doctor or pharmacist * This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. * If any of the side effects gets troublesome or serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. Your medicine is called Persantin 100mg Tablets, but will be reffered to as Persantin Tablets throughout this leaflet. IN THIS LEAFLET: What Persantin Tablets are and what they are used for Before you take Persantin Tablets How to take Persantin Tablets Possible side effects How to store Persantin Tablets Further information WHAT PERSANTIN TABLETS ARE AND WHAT THEY ARE USED FOR The name of your medicine is Persantin Tablets. It contains a medicine called Dipyridamole. This belongs to a group of medicines called ‘anti-thrombotic agents’, which are used to help stop blood clots forming. Persantin Tablets help stop blood clots which may occur if you have had your heart valves replaced. BEFORE YOU TAKE PERSANTIN TABLETS DO NOT TAKE PERSANTIN TABLETS IF YOU ARE ALLERGIC (HYPERSENSITIVE) TO: * Dipyridamole Any of the other ingredients of Persantin Tablets (see section 6: Further information) TAKE SPECIAL CARE WITH PERSANTIN TABLETS Check with your doctor or pharmacist before taking your medicine if: * You have angina or other heart problems (including heart valve or circulation problems) or have had a recent heart attack * You have myasthenia gravis (a rare muscle problem) * You have any bleeding problems * You are pregnant or planning to become pregnant or are breast-feeding * You have been told by your doctor that you have an intolerance to some sugars If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Persantin Table Les hele dokumentet
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dipyridamole Tablets 100mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Dipyridamole 100 mg Also contains 96.0 mg of lactose and 107.20 mg of sucrose. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Sugar-coated tablet White biconvex sugar-coated tablets with 9.5 mm in diameter approximately and plain on both sides. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS As an adjunct to oral anti-coagulation for prophylaxis of thromboembolism associated with prosthetic heart valves. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults: 300-600 mg daily in three or four doses. Paediatric population: Dipyridamole is not recommended for children. Elderly: As for adults. METHOD OF ADMINISTRATION Dipyridamole is taken by mouth, and should usually be taken before meals. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with known cardiac conduction difficulties or dysrhythmias. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Dipyridamole is a potent vasodilator and should be used with caution in patients with rapidly worsening angina, sub-valvular aortic stenosis or haemodynamic instability (e.g. decompensated heart failure) associated with a recently sustained myocardial infarction. Patients being treated with regular oral doses of Dipyridamole should not receive additional intravenous Dipyridamole. Clinical experience suggests that patients being treated with oral dipyridamole who also required pharmacological stress testing with intravenous dipyridamole, should discontinue drugs containing oral dipyridamole for twenty-four hours prior to stress testing. Dipyridamole should be used with caution in patients with coagulation disorders. In patients with myasthenia gravis, readjustment of therapy may be necessary after changes in dipyridamole dosage (see Drug Interactions). A small number of cases have been reported in which unconjugated dipyridamole was shown to Les hele dokumentet